NSTEMI accounts for approximately 70% of all ACS presentations and is caused by partial or intermittent coronary artery occlusion with biomarker evidence of myocardial necrosis (troponin elevation with a rise/fall pattern) in the absence of ST-segment elevation on ECG. [1] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.
1. History
- Chest discomfort at rest is the most common symptom (~79% men, ~74% women); described as pressure, squeezing, heaviness, or tightness [1]
- Radiation to left arm, jaw, neck, back, or epigastrium
- Duration typically >20 minutes; may be intermittent
- Associated symptoms: dyspnea, diaphoresis, nausea/vomiting, lightheadedness
- Atypical presentations are common: ~40% of men and ~48% of women present with nonspecific symptoms (dyspnea, fatigue, weakness) either alone or with chest pain [1]
- Timing: onset at rest or with minimal exertion; crescendo pattern of previously stable angina
- Important negatives: pleuritic quality, positional changes, reproducibility with palpation (though these do not reliably exclude ACS)
2. Alarm Features
- Hemodynamic instability (hypotension, tachycardia, signs of shock)
- Refractory chest pain despite medical therapy
- New or worsening heart failure (pulmonary edema, S3 gallop, new MR murmur) [2-3]
- Sustained ventricular tachycardia or ventricular fibrillation
- Dynamic or widespread ST-segment depression
- Killip class III–IV (pulmonary edema or cardiogenic shock) [4]
- Rapidly rising troponin suggesting ongoing myonecrosis
- These features warrant emergent (<2 h) coronary angiography [3-4]
3. Medications
Acute Treatment
Contraindicated medications: Fibrinolytics are contraindicated in NSTE-ACS and may be harmful. [9] Prasugrel is absolutely contraindicated in patients with prior stroke/TIA (net harm: 23% vs 16% events). [6][10] NSAIDs (other than aspirin) should be discontinued.
P2Y₁₂ pretreatment: The 2025 ACC/AHA guidelines recommend against routine P2Y₁₂ pretreatment in NSTE-ACS patients with a planned early invasive strategy. [4]
4. Diet
- NPO if catheterization is anticipated
- Heart-healthy/Mediterranean-style diet on discharge (low sodium <2 g/day, limited saturated fats)
- Adequate hydration, especially pre- and post-contrast for catheterization
- Long-term: DASH diet or Mediterranean diet for secondary prevention
5. Review of Systems
- Cardiovascular: palpitations, syncope/presyncope, orthopnea, PND, lower extremity edema
- Pulmonary: dyspnea, pleuritic pain (consider PE, pneumothorax)
- GI: epigastric pain, heartburn, hematemesis/melena (bleeding risk, GI mimics)
- Neurological: focal deficits (stroke, prior CVA — impacts prasugrel eligibility)
- Musculoskeletal: reproducible chest wall tenderness (costochondritis mimic)
- Psychiatric: anxiety, panic symptoms
6. Collateral History and Family History
- Prior cardiac history: previous MI, PCI, CABG, known CAD
- Medication compliance (especially antiplatelet agents, statins)
- Substance use: cocaine, amphetamines (coronary vasospasm)
- Family history of premature CAD (first-degree relative: male <55 y, female <65 y)
- Social context: ability to obtain medications, follow-up access, cardiac rehab feasibility [5]
7. Risk Factors
- Traditional: hypertension, hyperlipidemia, diabetes mellitus, smoking, obesity (BMI >30), family history of premature CAD
- Additional: chronic kidney disease, peripheral arterial disease, prior ACS, sedentary lifestyle
- Emerging: cocaine/stimulant use, autoimmune/inflammatory conditions, HIV, prior chest radiation
8. Differential Diagnosis
Cannot-miss life-threatening diagnoses
- Aortic dissection — tearing pain radiating to back, pulse/BP differential, aortic regurgitation murmur
- Pulmonary embolism — pleuritic pain, dyspnea, tachycardia, hypoxia, risk factors for VTE
- Tension pneumothorax — unilateral absent breath sounds, tracheal deviation
- Esophageal rupture (Boerhaave) — post-emetic, subcutaneous emphysema
Other important differentials
- Myocarditis/pericarditis — diffuse ST changes, friction rub, pleuritic/positional pain
- Takotsubo cardiomyopathy — post-emotional/physical stress, apical ballooning
- Type 2 MI — supply-demand mismatch from sepsis, anemia, tachyarrhythmia, hypotension [4][11]
- MINOCA — MI with non-obstructive coronaries; consider plaque erosion, coronary spasm, SCAD [12]
- GI causes: GERD, esophageal spasm, peptic ulcer, biliary disease
- Musculoskeletal: costochondritis, cervical radiculopathy [13]
9. Past Medical History
- Prior MI, PCI (stent type and date), CABG
- Known coronary anatomy from prior catheterization
- Heart failure (EF), valvular disease
- CKD (impacts contrast use, anticoagulant dosing, troponin interpretation) [13]
- Bleeding history (GI bleed, hemorrhagic stroke — impacts antithrombotic selection)
- Prior stroke/TIA (contraindication to prasugrel) [6]
10. Physical Exam
- Vitals: BP in both arms (>15 mmHg difference → consider dissection), HR, RR, SpO₂, temperature [14]
- Cardiovascular: S3/S4 gallop, new murmur of mitral regurgitation (papillary muscle dysfunction), JVD
- Pulmonary: rales/crackles (pulmonary edema → Killip class), unequal breath sounds
- Extremities: cool/mottled (cardiogenic shock), peripheral edema, pulse deficits
- Abdominal: pulsatile mass (AAA), epigastric tenderness (GI mimic)
- Exam may be entirely normal in uncomplicated NSTEMI [13][15]
11. Lab Studies
12. Imaging
- Chest X-ray: assess for pulmonary edema, widened mediastinum (dissection), pneumothorax
- Bedside echocardiography: new wall motion abnormalities support diagnosis; assess EF, valvular function, pericardial effusion; useful when ongoing ischemia or hemodynamic instability [1]
- Coronary angiography: gold standard for defining coronary anatomy; timing based on risk stratification (see Disposition) [1]
- CCTA: may be used in low-to-intermediate risk patients to exclude obstructive CAD; normal CCTA eliminates need for further testing [1]
- Stress testing: for low-risk patients with negative serial troponins and non-ischemic ECG who are being considered for discharge without catheterization [18]
13. Special Tests
Risk Stratification Scores
- HEART Score/Pathway: Best validated for ED chest pain evaluation; score ≤3 with negative serial troponins identifies low-risk patients safe for discharge (<1% 30-day MACE) [11][15][19]
- TIMI Risk Score (UA/NSTEMI): 7 variables; score ≥3 associated with benefit from aggressive antithrombotic therapy and invasive strategy [13][20]
- GRACE Score: Superior to physician gestalt for predicting death/MI; score >140 favors early invasive strategy within 24 h [5]
Point-of-care tests: bedside echo, lung ultrasound (B-lines for pulmonary edema, sliding sign for pneumothorax)
14. ECG
- Obtain within 10 minutes of ED arrival [1][7]
- NSTEMI ECG findings (may be present in any combination or absent entirely): [1]
- ST-segment depression (~31%)
- T-wave inversions (~12%)
- ST depression + T-wave inversions (~16%)
- Normal or non-diagnostic ECG (~41%)
- Serial ECGs are essential — 5% of ACS patients have initially normal ECGs [7]
- Dynamic ST changes with symptoms are high-risk and favor early invasive strategy
- Obtain right-sided and posterior leads if inferior changes or clinical suspicion of posterior MI
- ECG findings that may obscure ischemia: LBBB, LVH with strain, ventricular pacing, digoxin effect [7]
- Dangerous patterns: new LBBB, Wellens syndrome (deep symmetric T-wave inversions in V2–V3), de Winter T-waves, diffuse ST depression with ST elevation in aVR (left main or severe 3-vessel disease)
15. Assessment
NSTEMI represents a spectrum from low-risk troponin-positive events to hemodynamically unstable presentations with ongoing myonecrosis. Key assessment points:
- Confirm diagnosis: ischemic symptoms + troponin rise/fall + absence of ST elevation [16]
- Distinguish Type 1 MI (atherothrombotic) from Type 2 MI (supply-demand mismatch) — management differs fundamentally [4][11]
- Risk-stratify using validated tools (HEART, TIMI, GRACE) to guide invasive vs. conservative strategy [5]
- Atypical presentations are common in women, elderly, and diabetic patients — maintain high clinical suspicion [1]
- Complications: arrhythmias, acute HF, mechanical complications (papillary muscle rupture, VSD), cardiogenic shock
16. Treatment Plan
Initial Stabilization (ED)
- Continuous cardiac monitoring, IV access, supplemental O₂ only if SpO₂ <90%
- Aspirin 162–325 mg (chewed) immediately [5]
- Nitroglycerin SL for ongoing pain (avoid if hypotensive, RV infarct, PDE-5 inhibitor use)
- Parenteral anticoagulation (UFH or enoxaparin) [7]
- Morphine only if pain refractory to nitrates (use cautiously — may reduce clopidogrel absorption)
Invasive Strategy Timing: [3-4]
Discharge Medications (ABCDE mnemonic): [13]
- Aspirin (indefinitely) + P2Y₁₂ inhibitor (≥12 months default; shorter if high bleeding risk) [5][21]
- Beta-blocker + BP control
- Cholesterol (high-intensity statin ± ezetimibe; add PCSK9 inhibitor if LDL ≥70 mg/dL on max statin) [5]
- Diabetes management + Diet
- Exercise + Education + cardiac rehab referral
17. Disposition
Admission criteria (all confirmed NSTEMI)
- All patients with Type 1 NSTEMI require hospital admission [11]
- Telemetry monitoring with duration based on cardiac risk [5]
- ICU/CCU for hemodynamic instability, ongoing ischemia, arrhythmias, Killip III–IV
Observation unit consideration
Early discharge considerations (post-PCI)
Specialist consultation triggers
- Cardiology consultation for all confirmed NSTEMI
- Cardiac surgery consultation if left main or severe 3-vessel disease identified on angiography
- Heart failure team if EF <40% or cardiogenic shock
18. Follow Up / Return Precautions
Follow-up timing: [14][22]
- High-risk patients: within 14 days of discharge
- Low-risk/revascularized patients: 2–6 weeks
- Cardiac rehabilitation referral for all NSTEMI patients [5]
- Cardiology follow-up recommended for all patients with Type 1 MI, Type 2 MI, or myocardial injury [11]
Return precautions — instruct patients to call 911 for
- Recurrent chest pain/pressure lasting >5 minutes unrelieved by nitroglycerin
- New or worsening shortness of breath
- Syncope or near-syncope
- Palpitations or feeling of rapid/irregular heartbeat
- Signs of bleeding: black/tarry stools, blood in urine, unusual bruising, prolonged bleeding from cuts
Patient counseling
- Medication adherence is critical — do not stop DAPT without consulting cardiology (risk of stent thrombosis) [10][21]
- Smoking cessation
- Expected recovery: gradual return to activity; avoid heavy lifting for 1–2 weeks post-PCI
- Cardiac rehab improves outcomes and should be attended
The following figure from the 2014 AHA/ACC guidelines illustrates the management algorithm for NSTE-ACS, including both ischemia-guided and early invasive pathways:
References
1. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. — Bhatt DL, Lopes RD, Harrington RA. The Journal of the American Medical Association. 2022.
2. Practical Implementation of the Guidelines for Unstable Angina/Non-St-Segment Elevation Myocardial Infarction in the Emergency Department: A Scientific Statement From the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in Collaboration With the Society of Chest Pain Centers. — Gibler WB, Cannon CP, Blomkalns AL, et al. Circulation. 2005.
3. Acute Myocardial Infarction. — Reed GW, Rossi JE, Cannon CP. Lancet. 2017.
4. Acute Coronary Syndromes. — Bergmark BA, Mathenge N, Merlini PA, Lawrence-Wright MB, Giugliano RP. Lancet. 2022.
5. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Rao SV, O'Donoghue ML, Ruel M, et al. Journal of the American College of Cardiology. 2025.
6. Management of Acute Coronary Syndrome. — Vohra AS, Alexander JT, Shah AP. The Journal of the American Medical Association. 2026.
7. Acute Coronary Syndrome: Diagnosis and Initial Management. — Nohria R, Viera AJ. American Family Physician. 2024.
8. Routine Invasive Strategies Versus Selective Invasive Strategies for Unstable Angina and Non-St Elevation Myocardial Infarction in the Stent Era. — Fanning JP, Nyong J, Scott IA, Aroney CN, Walters DL. The Cochrane Database of Systematic Reviews. 2016.
9. Acute Myocardial Infarction. — Anderson JL, Morrow DA. The New England Journal of Medicine. 2017.
10. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. — Kamran H, Jneid H, Kayani WT, et al. The Journal of the American Medical Association. 2021.
11. 2022 ACC Expert Consensus Decision Pathway on the Evaluation and Disposition of Acute Chest Pain In the Emergency Department: A Report of the American College of Cardiology Solution Set Oversight Committee. — Kontos MC, de Lemos JA, Deitelzweig SB, et al. Journal of the American College of Cardiology. 2022.
12. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. — Tamis-Holland JE, Jneid H, Reynolds HR, et al. Circulation. 2019.
13. 2014 AHA/ACC Guideline for the Management of Patients With Non-St-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. — Amsterdam EA, Wenger NK, Brindis RG, et al. Journal of the American College of Cardiology. 2014.
14. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-St-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. — Wright RS, Anderson JL, Adams CD, et al. Journal of the American College of Cardiology. 2011.
15. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. — Gulati M, Levy PD, Mukherjee D, et al. Journal of the American College of Cardiology. 2021.
16. Fourth Universal Definition of Myocardial Infarction (2018). — Thygesen K, Alpert JS, Jaffe AS, et al. Journal of the American College of Cardiology. 2018.
17. Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians. — McCarthy CP, Raber I, Chapman AR, et al. JAMA Cardiology. 2019.
18. 2015 ACR/ACC/AHA/AATS/ACEP/ASNC/NASCI/SAEM/SCCT/SCMR/SCPC/SNMMI/STR/STS Appropriate Utilization of Cardiovascular Imaging in Emergency Department Patients With Chest Pain: A Joint Document of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Appropriate Use Criteria Task Force. — Rybicki FJ, Udelson JE, Peacock WF, et al. Journal of the American College of Cardiology. 2016.
19. Comparison of Heart, Grace and TIMI Scores to Predict Major Adverse Cardiac Events From Chest Pain in a Spanish Health Care Region. — Arispe INSR, Sol J, Gil AC, et al. Scientific Reports. 2023.
20. Thrombolysis in Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8. — Sabatine MS, Braunwald E. Journal of the American College of Cardiology. 2021.
21. Management of Antithrombotic Therapy after Acute Coronary Syndromes. — Rodriguez F, Harrington RA. The New England Journal of Medicine. 2021.
22. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-St-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-St-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. — Anderson JL, Adams CD, Antman EM, et al. Journal of the American College of Cardiology. 2007.